{"id":48567,"date":"2025-11-18T16:38:06","date_gmt":"2025-11-18T08:38:06","guid":{"rendered":"https:\/\/flcube.com\/?p=48567"},"modified":"2025-11-18T16:38:06","modified_gmt":"2025-11-18T08:38:06","slug":"hengruis-hrs-4642-kras-g12d-inhibitor-wins-nmpa-nod-for-phase-1b-2-solid-tumor-trials","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48567","title":{"rendered":"Hengrui&#8217;s HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b\/2 Solid Tumor Trials"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>) announced that <strong>HRS\u20114642<\/strong>, a home\u2011developed KRAS G12D inhibitor formulated as a liposome, has received <strong>NMPA approval<\/strong> to launch a Phase\u202f1b\/2 clinical trial in patients with KRAS G12D\u2011mutated solid tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>HRS\u20114642 injection<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Hengrui Pharmaceuticals<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Phase\u202f1b\/2 trial nod<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>KRAS G12D mutation<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Solid tumors (KRAS G12D\u2011mutated)<\/td><\/tr><tr><td><strong>Next Step<\/strong><\/td><td>Dosing of first patient expected Q1\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile\">Drug Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> KRAS G12D inhibitor, liposome formulation<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Specifically binds to KRAS G12D, inhibiting downstream MEK and ERK phosphorylation to exert anti\u2011tumor effects<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Home\u2011developed by Hengrui; liposomal delivery aims to improve tumor targeting and tolerability<\/li>\n\n\n\n<li><strong>Pipeline Status:<\/strong> First KRAS G12D asset from a Chinese biopharma to reach late\u2011stage development |<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-design\">Clinical Trial Design<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Phase<\/strong><\/td><td>Phase\u202f1b\/2 (dose\u2011expansion and signal\u2011finding)<\/td><\/tr><tr><td><strong>Primary Objectives<\/strong><\/td><td>Safety, tolerability, efficacy (ORR, DCR, PFS)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>KRAS G12D\u2011mutated solid tumor patients<\/td><\/tr><tr><td><strong>Combination Arms<\/strong><\/td><td>SHR\u20111701 (PD\u2011L1\/TGF\u2011\u03b2RII), SHR\u20117367 (FAP\/CD40), SHR\u20118068 (CTLA\u20114), adebrelimab (PD\u2011L1), bevacizumab (VEGF)<\/td><\/tr><tr><td><strong>Endpoints<\/strong><\/td><td>ORR, DCR, PFS, OS, safety profile<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>KRAS G12D Landscape:<\/strong> KRAS G12D mutations occur in ~10\u201112% of pancreatic, ~3\u20114% of colorectal, and ~1\u20112% of lung cancers in China, representing an addressable market of <strong>>80,000 patients annually<\/strong>.<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> First KRAS G12D inhibitor from a Chinese company to enter Phase\u202f1b\/2; global competitors include <strong>Mirati\u2019s MRTX1133<\/strong> (preclinical) and <strong>Revolution\u2019s RMC\u20119805<\/strong> (Phase\u202f1).<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project China peak sales potential of <strong>\u00a51.5\u20112.0\u202fbillion<\/strong> (~US$200\u2011270\u202fmillion) if approved, assuming 30% market share of KRAS G12D\u2011positive patients by 2035.<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Multi\u2011drug combo strategy leverages Hengrui\u2019s extensive immuno\u2011oncology pipeline, potentially creating synergistic regimens that could differentiate HRS\u20114642 from monotherapy approaches.<\/li>\n\n\n\n<li><strong>Next Catalysts:<\/strong> Initial safety and efficacy data expected at a major oncology conference in late\u202f2026; dosing of first patient triggers a <strong>US$5\u202fmillion<\/strong> milestone payment from Hengrui\u2019s R&amp;D partnership fund.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding HRS\u20114642\u2019s clinical development, regulatory pathway, and commercial potential. Actual results may differ materially due to risks including clinical trial outcomes, safety profiles, and competitive dynamics in the KRAS inhibitor market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025111700962_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025111700962_c.\"><\/object><a id=\"wp-block-file--media-ab9cafc9-8fb9-47ec-9457-47c38b704b93\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025111700962_c.pdf\">2025111700962_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2025111700962_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-ab9cafc9-8fb9-47ec-9457-47c38b704b93\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20114642, a home\u2011developed KRAS&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48572,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,62,4228,852],"class_list":["post-48567","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui&#039;s HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b\/2 Solid Tumor Trials - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20114642, a home\u2011developed KRAS G12D inhibitor formulated as a liposome, has received NMPA approval to launch a Phase\u202f1b\/2 clinical trial in patients with KRAS G12D\u2011mutated solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48567\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui&#039;s HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b\/2 Solid Tumor Trials\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20114642, a home\u2011developed KRAS G12D inhibitor formulated as a liposome, has received NMPA approval to launch a Phase\u202f1b\/2 clinical trial in patients with KRAS G12D\u2011mutated solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48567\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-18T08:38:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1808.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48567#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48567\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui&#8217;s HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b\\\/2 Solid Tumor Trials\",\"datePublished\":\"2025-11-18T08:38:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48567\"},\"wordCount\":395,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48567#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1808.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48567#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48567\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48567\",\"name\":\"Hengrui's HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b\\\/2 Solid Tumor Trials - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48567#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48567#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1808.webp\",\"datePublished\":\"2025-11-18T08:38:06+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20114642, a home\u2011developed KRAS G12D inhibitor formulated as a liposome, has received NMPA approval to launch a Phase\u202f1b\\\/2 clinical trial in patients with KRAS G12D\u2011mutated solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48567#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48567\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48567#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1808.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1808.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui's HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b\\\/2 Solid Tumor Trials\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48567#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui&#8217;s HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b\\\/2 Solid Tumor Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui's HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b\/2 Solid Tumor Trials - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20114642, a home\u2011developed KRAS G12D inhibitor formulated as a liposome, has received NMPA approval to launch a Phase\u202f1b\/2 clinical trial in patients with KRAS G12D\u2011mutated solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48567","og_locale":"en_US","og_type":"article","og_title":"Hengrui's HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b\/2 Solid Tumor Trials","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20114642, a home\u2011developed KRAS G12D inhibitor formulated as a liposome, has received NMPA approval to launch a Phase\u202f1b\/2 clinical trial in patients with KRAS G12D\u2011mutated solid tumors.","og_url":"https:\/\/flcube.com\/?p=48567","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-18T08:38:06+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1808.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48567#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48567"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui&#8217;s HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b\/2 Solid Tumor Trials","datePublished":"2025-11-18T08:38:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48567"},"wordCount":395,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48567#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1808.webp","keywords":["Cancer","Clinical trial approval \/ initiation","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48567#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48567","url":"https:\/\/flcube.com\/?p=48567","name":"Hengrui's HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b\/2 Solid Tumor Trials - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48567#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48567#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1808.webp","datePublished":"2025-11-18T08:38:06+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that HRS\u20114642, a home\u2011developed KRAS G12D inhibitor formulated as a liposome, has received NMPA approval to launch a Phase\u202f1b\/2 clinical trial in patients with KRAS G12D\u2011mutated solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48567#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48567"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48567#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1808.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1808.webp","width":1080,"height":608,"caption":"Hengrui's HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b\/2 Solid Tumor Trials"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48567#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui&#8217;s HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b\/2 Solid Tumor Trials"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1808.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48567","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48567"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48567\/revisions"}],"predecessor-version":[{"id":48573,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48567\/revisions\/48573"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48572"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48567"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48567"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48567"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}